Despite the fact we have quite significantly changed our assumptions after extensive talks with management, our target price does not move much. On the one hand, it is boosted by the NAV valuation based on future sales multiples of the products to be launched from FY24 onwards but, on the other, it is penalised by short-term losses. Actually, the peer-based comparison is very unfavourable for Crossject, considering that it will not generate any turnover, thus results, before FY24.